Published in J Clin Invest on December 01, 2004
Functions of S100 proteins. Curr Mol Med (2013) 2.43
Gene therapy in heart failure. Circ Res (2008) 1.79
Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation (2006) 1.73
S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol (2011) 1.68
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med (2011) 1.54
Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. Nat Rev Cardiol (2011) 1.49
Gene therapy for heart failure. Circ Res (2012) 1.46
Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther (2010) 1.41
The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol Cell Biol (2006) 1.41
Mechanisms of altered Ca²⁺ handling in heart failure. Circ Res (2013) 1.37
Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. J Mol Cell Cardiol (2010) 1.32
S100A1 binds to the calmodulin-binding site of ryanodine receptor and modulates skeletal muscle excitation-contraction coupling. J Biol Chem (2007) 1.23
S100A1 and calmodulin compete for the same binding site on ryanodine receptor. J Biol Chem (2008) 1.23
Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol (2007) 1.16
Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol (2012) 1.15
S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol (2009) 1.13
Gene therapy to treat cardiovascular disease. J Am Heart Assoc (2013) 1.13
Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol (2011) 1.11
Domestication of the cardiac mitochondrion for energy conversion. J Mol Cell Cardiol (2009) 1.10
The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition. Circ Res (2010) 1.07
Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol (2010) 1.05
Potential of gene therapy as a treatment for heart failure. J Clin Invest (2013) 1.04
Dot1a contains three nuclear localization signals and regulates the epithelial Na+ channel (ENaC) at multiple levels. Am J Physiol Renal Physiol (2010) 1.02
Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci (2008) 1.00
S100A1: a multifaceted therapeutic target in cardiovascular disease. J Cardiovasc Transl Res (2010) 0.96
Characterization of calumenin-SERCA2 interaction in mouse cardiac sarcoplasmic reticulum. J Biol Chem (2009) 0.96
S100A1: Structure, Function, and Therapeutic Potential. Curr Chem Biol (2009) 0.95
PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity. EMBO Mol Med (2014) 0.91
S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function. J Biomed Biotechnol (2010) 0.89
S100A1 and calmodulin regulation of ryanodine receptor in striated muscle. Cell Calcium (2011) 0.89
Altered myocardial calcium cycling and energetics in heart failure-a rational approach for disease treatment. Cell Metab (2015) 0.89
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res (2015) 0.89
Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications. Hum Gene Ther (2013) 0.85
Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther (2013) 0.83
Cardiac gene therapy. Semin Thorac Cardiovasc Surg (2010) 0.83
Model-specific selection of molecular targets for heart failure gene therapy. J Gene Med (2011) 0.83
S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4. EMBO Mol Med (2014) 0.82
Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1. Am J Physiol Heart Circ Physiol (2013) 0.81
Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther (2013) 0.81
Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies. Biochim Biophys Acta (2012) 0.80
The S100 protein family and its application in cardiac diseases. World J Emerg Med (2010) 0.77
AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling. F1000Prime Rep (2013) 0.77
S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction. Mol Ther (2015) 0.77
Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart. J Cardiovasc Transl Res (2008) 0.77
Gene therapy for heart failure: where do we stand? Curr Cardiol Rep (2013) 0.76
S100A1 in human heart failure: lack of recovery following left ventricular assist device support. Circ Heart Fail (2014) 0.76
S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats. Mol Med Rep (2016) 0.75
Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: a systematic review. Heart Fail Rev (2016) 0.75
X-ray crystal structure of human calcium-bound S100A1. Acta Crystallogr F Struct Biol Commun (2017) 0.75
S100A1 Protein Does Not Compete with Calmodulin for Ryanodine Receptor Binding but Structurally Alters the Ryanodine Receptor·Calmodulin Complex. J Biol Chem (2016) 0.75
Differential effects of S100 proteins A2 and A6 on cardiac Ca(2+) cycling and contractile performance. J Mol Cell Cardiol (2014) 0.75
Multifaceted role of β-arrestins in inflammation and disease. Genes Immun (2015) 0.75
Gene therapy for myocardial infarction-associated congestive heart failure: how far have we got? Dialog Cardiovasc Med (2009) 0.75
Influence of doxazosin on biosynthesis of S100A6 and atrial natriuretic factor peptides in the heart of spontaneously hypertensive rats. Exp Biol Med (Maywood) (2015) 0.75
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Cardiac excitation-contraction coupling. Nature (2002) 18.48
Intracellular and extracellular roles of S100 proteins. Microsc Res Tech (2003) 3.70
Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation (1999) 3.19
Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A (2000) 2.45
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol (2002) 2.26
Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A (1998) 2.19
Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res (1998) 2.19
Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation (2000) 2.01
Molecular basis of calmodulin binding to cardiac muscle Ca(2+) release channel (ryanodine receptor). J Biol Chem (2003) 1.80
Intracellular [Na+] and Na+ pump rate in rat and rabbit ventricular myocytes. J Physiol (2002) 1.67
[Na+]i handling in the failing human heart. Cardiovasc Res (2003) 1.51
Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol (2002) 1.43
Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem (2003) 1.43
S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci U S A (2001) 1.42
Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta (1996) 1.29
Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). J Biol Chem (2003) 1.25
Interaction of S100A1 with the Ca2+ release channel (ryanodine receptor) of skeletal muscle. Biochemistry (1997) 1.22
The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibers. J Biol Chem (2003) 1.11
Calcium and the heart: a question of life and death. J Clin Invest (2003) 1.09
Ca2+ -dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+ -ATPase2a and phospholamban in the human heart. Biochem Biophys Res Commun (2003) 1.02
The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol (2002) 1.01
S100a0 (alpha alpha) protein in cardiac muscle. Isolation from human cardiac muscle and ultrastructural localization. Eur J Biochem (1988) 1.00
Direct demonstration of Ca2+ binding defects in sarco-endoplasmic reticulum Ca2+ ATPase mutants overexpressed in COS-1 cells transfected with adenovirus vectors. J Biol Chem (1998) 1.00
S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med (2004) 0.91
The myocardial protein S100A1 plays a role in the maintenance of normal gene expression in the adult heart. Mol Cell Biochem (2003) 0.90
High-energy phosphates in quiescent, beating and contracted cardiac cells. Biochim Biophys Acta (1988) 0.80
Universal definition of myocardial infarction. Circulation (2007) 11.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Hypertrophy of the heart: a new therapeutic target? Circulation (2004) 4.45
MicroRNA-34a regulates cardiac ageing and function. Nature (2013) 4.03
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem (2009) 3.24
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 3.15
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res (2010) 3.00
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation (2006) 2.67
The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A (2009) 2.66
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation (2006) 2.58
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med (2007) 2.48
Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet (2011) 2.45
Circadian profile of cardiac autonomic nervous modulation in healthy subjects: differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol (2003) 2.41
Cardiac myosin light chain-2: a novel essential component of thick-myofilament assembly and contractility of the heart. Circ Res (2006) 2.36
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J (2005) 2.29
Integrin-linked kinase, a novel component of the cardiac mechanical stretch sensor, controls contractility in the zebrafish heart. Genes Dev (2006) 2.29
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res (2008) 2.22
Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med (2009) 2.21
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation (2008) 2.17
Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction. Circ Res (2012) 2.16
Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation. Clin Res Cardiol (2014) 2.15
Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem (2011) 2.14
Toward the blood-borne miRNome of human diseases. Nat Methods (2011) 2.14
Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat Med (2004) 2.11
Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol (2011) 2.10
Nexilin mutations destabilize cardiac Z-disks and lead to dilated cardiomyopathy. Nat Med (2009) 2.08
Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol (2003) 2.08
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res (2006) 2.08
Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res (2006) 2.07
Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation (2011) 2.06
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation (2013) 2.03
Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol (2009) 2.03
Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol (2012) 2.02
The sarcomeric Z-disc: a nodal point in signalling and disease. J Mol Med (Berl) (2006) 1.99
Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A (2008) 1.93
C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation (2012) 1.90
MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol (2010) 1.87
Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart (2010) 1.87
A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med (2007) 1.86
Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension (2010) 1.84
Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol (2012) 1.84
Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension (2013) 1.83
Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J (2008) 1.83
Abnormal frequency-dependent responses represent the pathophysiologic signature of contractile failure in human myocardium. J Mol Cell Cardiol (2004) 1.81
Gene therapy in heart failure. Circ Res (2008) 1.79
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol (2013) 1.78
Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1,493 consecutive patients: assessment of myocardial wall motion and perfusion. J Am Coll Cardiol (2010) 1.78
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res (2011) 1.76
Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A (2004) 1.76
Myocardial AKT: the omnipresent nexus. Physiol Rev (2011) 1.76
Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium. Circulation (2002) 1.73
Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation (2006) 1.73
Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab (2012) 1.73
Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation (2007) 1.73
Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol (2013) 1.71
High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. Clin Sci (Lond) (2010) 1.70
Patient alert in implantable cardioverter defibrillators: toy or tool? J Am Coll Cardiol (2004) 1.68
S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol (2011) 1.68
Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res (2009) 1.67
β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res (2012) 1.66
Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. Eur Heart J (2013) 1.65
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA (2003) 1.64
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene (2003) 1.64
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation (2006) 1.64